 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.
SUMMARIES FOR PATIENTS
Blood Clots in People with the Factor V Leiden Mutation
4 September 2001 | Volume 135 Issue 5 | Page S34
Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians-American Society of Internal Medicine.
The summary below is from the full report titled "A Prospective Study of Asymptomatic Carriers of the Factor V Leiden Mutation To Determine the Incidence of Venous Thromboembolism." It is in the 4 September 2001 issue of Annals of Internal Medicine (volume 135, pages 322-327). The authors are S Middeldorp, JR Meinardi, MMW Koopman, ECM van Pampus, K Hamulyák, J van der Meer, MH Prins, and HR Büller.
What is the problem and what is known about it so far?
Blood clots occur commonly in deep veins in the legs. Pieces of these clots, known as emboli, can break off and travel through the bloodstream, blocking arteries in the lungs. These blood clots and emboli can cause serious symptoms and death. Surgery, pregnancy, trauma, hormone therapy, and inherited blood disorders increase risks for blood clots and emboli. Factor V Leiden is one of these inherited disorders. Although factor V Leiden is a common genetic defect, the actual incidence of clots and emboli among people with the defect is unknown.
Why did the researchers do this particular study?
To find out how often blood clots and emboli occur in people with the factor V Leiden mutation.
Who was studied?
470 relatives of patients with factor V Leiden mutation and known blood clots or emboli. All of the relatives also had factor V Leiden mutation, but none had histories of blood clots or emboli.
How was the study done?
Patients with blood clots or emboli and factor V Leiden mutation were identified from three hospitals in the Netherlands. The researchers contacted parents, siblings, and children of the patients. These relatives were asked if they had ever had blood clots in their legs or lungs, and their blood was tested for factor V Leiden mutation. Relatives with factor V Leiden mutation and no history of blood clots were taught how to watch for symptoms and signs of clots. Every 6 months for about 3 years, they were asked about blood clots and related risk situations, such as surgery, pregnancy, or taking hormone pills. Medical charts of those who reported blood clots were reviewed to confirm diagnoses.
What did the researchers find?
Nine relatives had blood clots in the deep veins of the legs or emboli to their lungs. Four instances occurred in relatives with no risk factors, and five occurred in relatives with increased risk for blood clots (1 after surgery, 1 during estrogen replacement therapy, and 3 during use of birth control pills). The overall occurrence rate of deep vein thrombosis or lung emboli was 0.58% per year. The rate was 1.8% per year of birth control pill use; 2.9% per year of hormone replacement therapy use; and 3.5% per episode of surgery, trauma, or prolonged immobilization.
What were the limitations of the study?
Precise estimates of rates in people at higher risk, such as those undergoing surgery or taking birth control pills, were not possible because few people with these situations were studied.
What are the implications of the study?
The yearly occurrence rate of deep vein clots or lung emboli among people with factor V Leiden mutation and no history of clots or emboli seems low (about 6 events per 1000 people with the mutation). Although this rate is five to six times higher than that seen in the general population, the authors concluded that the rate is too low to justify routine genetic screening of family members of patients with clots and factor V Leiden mutation.
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  M. Coppens, M. H. van de Poel, I. Bank, K. Hamulyak, J. van der Meer, N. J. Veeger, M. H. Prins, H. R. Buller, and S. Middeldorp A prospective cohort study on the absolute incidence of venous thromboembolism and arterial cardiovascular disease in asymptomatic carriers of the prothrombin 20210A mutation Blood, October 15, 2006; 108(8): 2604 - 2607. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Curb, R. L. Prentice, P. F. Bray, R. D. Langer, L. Van Horn, V. M. Barnabei, M. J. Bloch, M. G. Cyr, M. Gass, L. Lepine, et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Arch Intern Med, April 10, 2006; 166(7): 772 - 780. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Dizon-Townson, C. Miller, B. Sibai, C. Y. Spong, E. Thom, G. Wendel Jr, K. Wenstrom, P. Samuels, M. A. Cotroneo, A. Moawad, et al. The Relationship of the Factor V Leiden Mutation and Pregnancy Outcomes for Mother and Fetus Obstet. Gynecol., September 1, 2005; 106(3): 517 - 524. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Cushman Inherited Risk Factors for Venous Thrombosis Hematology, January 1, 2005; 2005(1): 452 - 457. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Cushman, L. H. Kuller, R. Prentice, R. J. Rodabough, B. M. Psaty, R. S. Stafford, S. Sidney, F. R. Rosendaal, and for the Women's Health Initiative Investigators Estrogen Plus Progestin and Risk of Venous Thrombosis JAMA, October 6, 2004; 292(13): 1573 - 1580. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. K. Wittkowsky Anticoagulation in Hypercoagulable Conditions: Special Considerations in the Treatment and Prevention of Venous Thromboembolism Journal of Pharmacy Practice, October 1, 2004; 17(5): 308 - 316. [Abstract] [PDF]
|
|
|
|
 |
|
 S. E. Humphries, P. M. Ridker, and P. J. Talmud Genetic Testing for Cardiovascular Disease Susceptibility: A Useful Clinical Management Tool or Possible Misinformation? Arterioscler. Thromb. Vasc. Biol., April 1, 2004; 24(4): 628 - 636. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. I. Weitz, S. Middeldorp, W. Geerts, and J. A. Heit Thrombophilia and New Anticoagulant Drugs Hematology, January 1, 2004; 2004(1): 424 - 438. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. L. Orwoll Risk for Venous Thromboembolism in Carriers of the Factor V Leiden Mutation Ann Intern Med, January 7, 2003; 138(1): 76 - 76. [Full Text] [PDF]
|
|
|
|
 |
|
 W. Burke Genetic Testing N. Engl. J. Med., December 5, 2002; 347(23): 1867 - 1875. [Full Text] [PDF]
|
|
|
|
|
|
M. Procopiou Genetic Hypercoagulability Syndromes: Does Testing Really Matter? Arch Intern Med, August 12, 2002; 162(15): 1784 - 1785. [Full Text] [PDF]
|
|
|
|
 |
|
 H. V Joffe and S. Z Goldhaber Laboratory thrombophilias and venous thromboembolism Vascular Medicine, May 1, 2002; 7(2): 93 - 102. [Abstract] [PDF]
|
|
|
|
|
|
C. E. Ettingshausen, K. Kurnik, R. Schobess, W. D. Kreuz, S. Halimeh, H. Pollman, U. Nowak-Gottl ;, J. M. Journeycake, and G. R. Buchanan Catheter-related thrombosis in children with hemophilia A: evidence of a multifactorial disease Blood, February 15, 2002; 99(4): 1499 - 1499. [Full Text] [PDF]
|
|
|
|
 |
|
 Low Incidence of Thromboembolism in Asymptomatic Carriers of Factor V Leiden Journal Watch (General), September 21, 2001; 2001(921): 2 - 2. [Full Text]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Article
